OBJECTIVE: This study explored whether average urinary estrogen metabolites in breast cancer high-risk women can be used to identify a subgroup of women at particularly high risk to develop breast cancer, to which prevention strategies should be addressed. METHODS: The population consisted of 77 high-risk women, 30 breast cancer patients and 41 controls. All subjects answered a standardized questionnaire; height and weight and spot urine samples were also obtained. Urine hydroxyestrogen metabolites were measured in triplicate by enzyme immunoassay, and the estrogen metabolite ratios for each individual were calculated. RESULTS: The 2:16 OHE ratio (2-hydroxyestrone/16-alpha-hydroxyestrone) in women at high risk for breast cancer was similar to that observed in the breast cancer group (1.76 +/- 2.33 versus 1.29 +/- 0.80) and lower than in controls (2.47 +/- 1.14; P = 0.00). At the multivariate linear regression model, the 2:16 OHE ratio was significantly associated with diagnosis (P = 0.000 for both the high risk and breast cancer group versus the controls) and body mass index (P = 0.005), but not with age (P = 0.604), or smoking history (P = 0.478). CONCLUSIONS: This study suggests that lower urinary 2:16 OHE ratios are predictors of breast cancer risk. Profiling estrogen metabolites may identify women who are more probably to develop breast cancer within a population of women with known risk factors and may help to further elucidate the clinical relevance of urinary 2:16 OHE ratios as clinical markers and prognostic indicators in this population.
OBJECTIVE: This study explored whether average urinary estrogen metabolites in breast cancer high-risk women can be used to identify a subgroup of women at particularly high risk to develop breast cancer, to which prevention strategies should be addressed. METHODS: The population consisted of 77 high-risk women, 30 breast cancerpatients and 41 controls. All subjects answered a standardized questionnaire; height and weight and spot urine samples were also obtained. Urine hydroxyestrogen metabolites were measured in triplicate by enzyme immunoassay, and the estrogen metabolite ratios for each individual were calculated. RESULTS: The 2:16 OHE ratio (2-hydroxyestrone/16-alpha-hydroxyestrone) in women at high risk for breast cancer was similar to that observed in the breast cancer group (1.76 +/- 2.33 versus 1.29 +/- 0.80) and lower than in controls (2.47 +/- 1.14; P = 0.00). At the multivariate linear regression model, the 2:16 OHE ratio was significantly associated with diagnosis (P = 0.000 for both the high risk and breast cancer group versus the controls) and body mass index (P = 0.005), but not with age (P = 0.604), or smoking history (P = 0.478). CONCLUSIONS: This study suggests that lower urinary 2:16 OHE ratios are predictors of breast cancer risk. Profiling estrogen metabolites may identify women who are more probably to develop breast cancer within a population of women with known risk factors and may help to further elucidate the clinical relevance of urinary 2:16 OHE ratios as clinical markers and prognostic indicators in this population.
Authors: Valentina Paracchini; Paola Pedotti; Sara Raimondi; Seymour Garte; H Leon Bradlow; Daniel W Sepkovic; Emanuela Taioli Journal: Clin Chem Lab Med Date: 2005 Impact factor: 3.694
Authors: G C Kabat; C J Chang; J A Sparano; D W Sepkovie; X P Hu; A Khalil; R Rosenblatt; H L Bradlow Journal: Cancer Epidemiol Biomarkers Prev Date: 1997-07 Impact factor: 4.254
Authors: Francesmary Modugno; Kevin E Kip; Barbara Cochrane; Lewis Kuller; Thomas L Klug; Thomas E Rohan; Rowan T Chlebowski; Norman Lasser; Marcia L Stefanick Journal: Int J Cancer Date: 2006-03-01 Impact factor: 7.396
Authors: Geoffrey C Kabat; Erin S O'Leary; Marilie D Gammon; Daniel W Sepkovic; Susan L Teitelbaum; Julie A Britton; Mary B Terry; Alfred I Neugut; H Leon Bradlow Journal: Epidemiology Date: 2006-01 Impact factor: 4.822
Authors: MaryFran R Sowers; Sybil Crawford; Daniel S McConnell; John F Randolph; Ellen B Gold; Margaret K Wilkin; Bill Lasley Journal: J Nutr Date: 2006-06 Impact factor: 4.798
Authors: G Ursin; S London; F Z Stanczyk; E Gentzschein; A Paganini-Hill; R K Ross; M C Pike Journal: J Natl Cancer Inst Date: 1999-06-16 Impact factor: 13.506
Authors: Shubhankar Suman; Michael D Johnson; Albert J Fornace; Kamal Datta Journal: Int J Radiat Oncol Biol Phys Date: 2012-02-28 Impact factor: 7.038
Authors: Rachel H Mackey; Theresa J Fanelli; Francesmary Modugno; Jane A Cauley; Kathleen M McTigue; Maria Mori Brooks; Rowan T Chlebowski; JoAnn E Manson; Thomas L Klug; Kevin E Kip; J David Curb; Lewis H Kuller Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-08-29 Impact factor: 4.254
Authors: Dina Nikitina; Marcia Llacuachaqui; Daniel Sepkovic; H Leon Bradlow; Steven A Narod; Joanne Kotsopoulos Journal: Fam Cancer Date: 2015-06 Impact factor: 2.375